Metabolomics Market Size & Share, by Product & Services (Instruments, Bioinformatics Tools & Services); Application (Biomarker Discovery, Drug Discovery, Toxicology Testing, Functional Genomics, Personalized Medicine, Nutrigenomics); Indication (Cancer, Cardiovascular Disorders, Neurological Disorders); Techniques (Separation, Detection) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 515
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2033

Metabolomics Market size is poised to cross USD 5 Billion by the end of 2033, growing at a CAGR of 13% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of metabolomics was over USD 2 Billion. The increase in the adoption of metabolomics in precision medicine and the advancement of diagnostics to determine chronic diseases drive market growth during the forecast period. The increase in R&D expenditure in the pharmaceutical and biopharmaceutical industry and technological advancements in analytical techniques are expected to boost market growth. Over the past two decades, healthcare spending has increased significantly, reaching USD 8.5 trillion, or 9.8% of global GDP.

Using high-throughput analytical techniques, metabolomics researches the metabolome of cells, biofluids, tissues, or organisms to identify and measure changes in low molecular weight exogenous and endogenous compounds linked to disease processes. Multiple analytical techniques are needed given the complexity of the metabolome and the wide range of physiochemical characteristics of the metabolites. Nuclear magnetic resonance (NMR) and mass spectrometry (MS), along with separation methods including liquid chromatography (LC), gas chromatography (GC), and supercritical fluid chromatography (SFC), are the two analytical platforms that are used most frequently. From as little as 10 mg of tissue, 50 L of urine, and 500,000 cells, liquid chromatography (LC) combined with high-resolution MS systems to routinely detect and quantify dozens of metabolic characteristics. For instance, a conventional LC-MS-based metabolomics study with 30 samples typically generates more than 10 GB of data.

Get more information on this report: Request Free Sample PDF

Metabolomics Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Acceptance of Metabolomics in Personalized Medicine – Metabolite profiling in biological matrices is a major tool to discover biomarkers and personalized medicine. The metabolomics studies are involved in the identification of several biomarkers that involve complex clinical phenotypes using diverse biological systems. This helps to create personalized medicine to improve drug efficacy and reduce toxicity. Worldwide metabolomics represents more than 95% of the workload in clinical laboratories. Associating metabolomics with genomics, proteomics, and transcriptomics will aid to understand the mechanism of disease, and the pathophysiology of the target clinical phenotype.
  • Increased Incidence of Chronic Diseases – Chronic diseases affect health and quality of life. Chronic diseases such as diabetes, cancer, and heart disease are the most common causes of death in the U.S.  As per the Centers for Disease Control, every year 90% of the nation’s USD 3.8 trillion in healthcare costs are attributed to people with chronic diseases and mental health conditions.
  • Funding from Government and Private Authorities – The Investment Possibility of the Undiagnosed Disease Network (UDN) announced the establishment of a Metabolomics core that'd enhance clinical and laboratory findings and aid the Network in the diagnosis of patients with unknown disorders. Numerous government financing initiatives have been launched for advanced metabolomics research. For instance, to promote the interpretation of data from metabolomics research, the National Institute of Health (NIH), has granted a grant for USD 1.37 million.
  • Technological Advancements in Scientific Instruments – NIST developed a set using human urine materials to help in metabolomics QC materials. The set consists of pooled samples from female and male smokers and non-smokers. The set is qualitatively characterized by liquid chromatography, high-resolution mass spectrometry, and NMR to detect percent differences and metabolite fold changes for the top 20 metabolites in each urine material. The adoption and regular utilization of these QC materials will help to bring harmonization to the metabolomics field in its application in research, diagnostic, testing laboratories, and varied bio-relevant industrial processes.
  • Growing Healthcare Infrastructure – The rising demand for new digital products to replace old analog systems in the healthcare sector. Disease diagnosis and medical imaging is increasing the demand for innovation of technologically advanced equipment and installation of diagnostic devices.


  • High Price of Metabolomic Instruments - The cost and management of a group of analytical tools, that are either collectively quite expensive, or demand a sizeable amount of funds. Depending on the necessary triple, quadrupole, or high-resolution architecture, a modern gas chromatography coupled to mass spectrometry (GC-MS) system costs between USD 200k and USD 600k, a liquid chromatography coupled to mass spectrometry (LC-MS) system costs between USD 300k and USD 800k, and a nuclear magnetic resonance system cost more than USD 800k.
  • Need for Multiple Analytical Platforms
  • Complexity Increase in Interpreting Data

Metabolomics Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

USD 2 Billion

Forecast Year Market Size (2033)

USD 5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Metabolomics Segmentation

Indication (Cancer, Cardiovascular Disorders, Neurological Disorders)

The global metabolomics market is segmented and analyzed for demand and supply by indication into cancer, cardiovascular disorders, and neurological disorders. Out of these, the cancer segment is anticipated to hold the largest market size by the end of 2033 on account of the rising incidence of cancer patients is expected to boost the market growth. Lung cancer is the leading cause of death in men and women, more than a million new cancer cases and more than 6 million deaths occurred in 2020. Metabolomics application of Nuclear Magnetic Resonance technique and Mass Spectrometry is used to study cancer disease.

Our in-depth analysis of the global metabolomics market includes the following segments:  

       By Product & Services

  • Metabolomics Instruments
  • Metabolomics Bioinformatics Tools & Services

       By Application

  • Biomarker Discovery
  • Drug Discovery
  • Toxicology Testing
  • Functional Genomics
  • Personalized Medicine
  • Nutrigenomics

      By Indication

  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders


       By Metabolomics

  • Separation Techniques
  • Detection Techniques

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Metabolomics Industry - Regional Synopsis

Asia Pacific Market Forecast

The Asia Pacific metabolomics market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033, on the back of increasing demand for pharmaceutical and biopharmaceutical products developed in the regions of developing countries such as India and China. The demand for better medical care, government initiatives, healthcare awareness, and technological improvements are estimated to boost the market during the forecast period. The government of Japan issued more than USD 8 million to UNICEF East Asia and Pacific Regional Office to assist with digital immunization tools in Cambodia, Lao PDR, Mongolia, the Philippines, Timor-Leste, and Vietnam. These interventions indirectly reached about 13 million people along with over 1000 health facilities and more than 4000 health workers.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Metabolomics Landscape

    • Thermo Fisher Scientific
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Agilent Technologies
    • Biocrates Life Sciences AG
    • Bio-Rad Laboratories, Inc.
    • Bruker
    • Danaher
    • Human Metabolome Technologies America Inc.
    • LECO Corporation
    • Metabolon, Inc.
    • Shimadzu Corporation


In The News

  • Thermo Fischer Scientific in association with UC Davis launched a Center of Excellence in Clinical Metabolomics, a research collaboration to provide the metabolomics community with innovations that will develop standardized processes for the research community, optimized liquid chromatography-mass spectrometry (LC-MS) methods to support the rapid scale-up of large cohort studies.

  • Agilent Technologies announced a new range of products designed to increase capabilities for food testing, environmental screening, and metabolomics research to provide enhanced analytical and business outcomes for laboratories.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 515
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing acceptance of metabolomics in personalized medicine, increased incidence of chronic diseases, funding from government and private authorities are the major factors driving the growth of the metabolomics market.

The market is anticipated to attain a CAGR of 13% over the forecast period, i.e., 2023-2033.

The complexity increases in interpreting data, the high price of metabolomic instruments, and the scarcity of professionals are the challenges affecting the market growth.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Agilent Technologies, Biocrates Life Sciences AG, Bio-Rad Laboratories, Inc., Bruker, Danaher, Human Metabolome Technologies America Inc., LECO Corporation, Metabolon, Inc., Shimadzu Corporation., and others.

The company profiles are selected based on the revenues generated from the product segment, and the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product & services, application, indication, metabolomics, and by region.

The cancer segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Metabolomics Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying